Remove 2020 Remove Pharmaceutical Companies Remove Vaccines
article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment.

Vaccines 134
article thumbnail

The Pandemic Treaty and the opportunity to end ‘vaccine apartheid’

pharmaphorum

Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. The world was caught unprepared for the global pandemic that struck in 2020. Vaccine access for a price. There are now efforts to ensure that the same is not allowed to happen again.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Malaria vaccines must beat logistics issues for efficient access

Pharmaceutical Technology

As the prophylactic landscape for malaria has changed in recent years with vaccine approvals, major issues still remain with ensuring access in remote communities. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements. The Mosquirix vaccine contains two vials.

article thumbnail

Scientific evidence ‘on demand’? Proceedings from an expert roundtable

pharmaphorum

In 2020, the challenges of the COVID-19 pandemic greatly accelerated the pace of this evolution, with wide-reaching effects on many aspects of medical communications. A panel of industry experts gathered at the end of 2020 to identify some of these long-term effects, and the challenges and opportunities they pose. Conclusion.

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

article thumbnail

Three pillars of post-pandemic launch excellence

pharmaphorum

IQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity for companies to focus on and address in 2021. It is undeniable that 2020 was a particularly challenging year to launch non-COVID innovative prescription medicines.

article thumbnail

Pfizer: Pharma needs a business strategy for a digital world

pharmaphorum

Its chief digital and technology officer Lidia Fonseca offered a fascinating insight into how one biggest pharmaceutical companies – and one of those most closely associated with the pandemic (alongside the likes of BioNTech, Moderna and AstraZeneca) – has been transforming itself. Digital fluency and change.